Yes ... this is just the beginning. This little company has so many things going for it.
Nothing like having regular cash flow -- streaming in.
True, ACS will not endorse this company - but it is the change in paradigm - the ability to precisely target and bring in credibility to the PSA test - that is what ACS will go after.
"The ACS will likely not endorse our test directly"
You're right on with your thinking. The ACS doesn't support screening (as is now), only because the PSA doesn't detect prostate cancer - only elevated PSA levels. Thus, it only has a positive predictive value of about 25%! Who would endorse that? The predictive value of our genetic test for prostate cancer will have a predictive value of whatever the sensitivity is - because it's testing for the cancer itself. Anything close to 90% could be considered "gold standard."
Market Data 
Markets 
AI
